Document Detail


Cardiovascular structural alterations in hypertension: effect of treatment.
MedLine Citation:
PMID:  8743039     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Available data support the hypothesis that antihypertensive drugs may determine a significant regression of cardiac and vascular structural changes. Antihypertensive drugs that inhibit the renin-angiotensin or, to a lesser extent, the adrenergic system may more consistently and promptly reduce left ventricular hypertrophy (LVH) and vascular structural changes. It is possible that all antihypertensive agents, when used for long enough periods, will reduce LV mass, whereas only certain drugs will reduce mass within a period of few months, so that any difference among classes of antihypertensive drugs is more quantitative than absolute. However, a rapid reversal of LVH may be particularly important because reducing blood pressure in the presence of an elevated LV mass may be associated with impairment of coronary perfusion. Structural changes of small resistance arteries play a significant role in the genesis of increased vascular resistance in hypertension and in the maintainance of high blood pressure values. Studies in humans have demonstrated that minimal vascular resistance can be reduced with the use of different antihypertensive drugs, while a complete normalization of the media: lumen ratio was observed only with ACE inhibitors. Further studies are needed to assess the true clinical impact, in terms of reduced morbidity and mortality of reversal of cardiovascular structural changes in hypertensive patients. However, available studies indicate that reversal of LVH reduces the pathological consequences of increased left ventricular mass, and preliminary data suggest that complete regression of LVH may be associated to a decreased risk for cardiovascular events.
Authors:
E Agabiti-Rosei; M L Muiesan; D Rizzoni
Related Documents :
7608309 - Diltiazem: ten years of clinical experience in the treatment of hypertension.
3589239 - Hypertension case-finding in primary health care. experience from the skaraborg hyperte...
6439369 - Sources of error in recording the blood pressure of patients with hypertension in gener...
3280499 - Factors that contribute to resistant forms of hypertension. pharmacological considerati...
16298269 - Treatment of hypertension in chronic kidney disease.
14594569 - Management of hypertension emergencies.
17812529 - Supercooling of water to -92{degrees}c under pressure.
12757089 - Comparison of intraocular pressure profiles during cataract surgery by phacoemulsificat...
10063849 - Correlation of duplex sonography findings and portal pressure in 375 patients with port...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical and experimental hypertension (New York, N.Y. : 1993)     Volume:  18     ISSN:  1064-1963     ISO Abbreviation:  Clin. Exp. Hypertens.     Publication Date:    1996 Apr-May
Date Detail:
Created Date:  1996-10-24     Completed Date:  1996-10-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9305929     Medline TA:  Clin Exp Hypertens     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  513-22     Citation Subset:  IM    
Affiliation:
Cattedra di Semeiotica e Metodologia Medica, University of Brescia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / therapeutic use*
Arteries / drug effects,  pathology
Cardiovascular Diseases / prevention & control
Cardiovascular System / drug effects*,  pathology*,  physiopathology
Clinical Trials as Topic
Humans
Hypertension / drug therapy*,  pathology*,  physiopathology
Hypertrophy, Left Ventricular / drug therapy,  physiopathology
Meta-Analysis as Topic
Prognosis
Chemical
Reg. No./Substance:
0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Can the kidney prevent cardiovascular diseases?
Next Document:  Diuretics and risk of sudden death in hypertension--evidence and potential implications.